Convergence Investment Partners LLC Boosts Holdings in Natera, Inc. (NASDAQ:NTRA)

Convergence Investment Partners LLC lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 41.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,757 shares of the medical research company’s stock after purchasing an additional 803 shares during the period. Convergence Investment Partners LLC’s holdings in Natera were worth $436,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Wellington Management Group LLP increased its position in Natera by 205.4% in the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after buying an additional 1,883,481 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Natera by 3.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock worth $315,194,000 after acquiring an additional 85,236 shares during the last quarter. Geode Capital Management LLC increased its holdings in Natera by 7.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock worth $265,747,000 after acquiring an additional 143,825 shares during the last quarter. Maverick Capital Ltd. increased its holdings in Natera by 25.2% in the 3rd quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock worth $170,119,000 after acquiring an additional 269,706 shares during the last quarter. Finally, Castle Hook Partners LP increased its stake in shares of Natera by 27.4% in the third quarter. Castle Hook Partners LP now owns 1,140,090 shares of the medical research company’s stock worth $144,734,000 after purchasing an additional 245,505 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 78,553 shares of the business’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at $44,150,756.13. The trade was a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Solomon Moshkevich sold 4,858 shares of the business’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $166.59, for a total transaction of $809,294.22. Following the completion of the sale, the insider now directly owns 114,912 shares of the company’s stock, valued at $19,143,190.08. This represents a 4.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 295,772 shares of company stock worth $49,741,699. 7.60% of the stock is currently owned by corporate insiders.

Natera Stock Up 1.9 %

NTRA opened at $172.61 on Thursday. The business’s fifty day simple moving average is $168.03 and its 200 day simple moving average is $144.62. Natera, Inc. has a 52 week low of $68.03 and a 52 week high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a market cap of $22.79 billion, a PE ratio of -98.07 and a beta of 1.66.

Analyst Ratings Changes

Several equities analysts have recently weighed in on NTRA shares. JPMorgan Chase & Co. lifted their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Guggenheim lifted their price objective on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Morgan Stanley lifted their price target on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Robert W. Baird lifted their price target on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, Craig Hallum lifted their target price on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $165.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.